Delivery Order SPE2DB24D2010-SPE2DB25FAATH
- Not listed
- The Defense Logistics Agency (DLA) awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Scemblix 40 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp on April 29, 2025, for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, which must be completed by May 20, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Scemblix 40 mg tablets (60-count units) with a contract ceiling value of $39,778.50. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the pharmaceutical distributor. The contract is set to be completed by September 17, 2025, and performance will take place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) under a firm fixed-price contract. The order, issued on August 22, 2025, with an ultimate completion date of September 15, 2025, represents a competitively awarded, non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 tablets of Scemblix 40 mg, a pharmaceutical product, with completion scheduled for July 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency has awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units), with a completion deadline of September 26, 2025. This competitive, non-set-aside contract reflects firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract will be performed at the contractor's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Scemblix 40 mg tablets in quantities of 60s, with a contract ceiling value of $13,259.50. This firm fixed-price delivery order, with an ultimate completion date of August 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $26,519.00 to AmerisourceBergen Drug Corp for supply of Scemblix 40 mg tablets (60 count) on September 5, 2025, with completion targeted for September 26, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for the supply of Scemblix 40 mg tablets (60-count units) on August 7, 2025, with an ultimate completion date of August 28, 2025. The contract utilizes firm fixed price terms and was awarded through open competition with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, performed as the prime contractor for this pharmaceutical delivery. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,259.50 to AmerisourceBergen Drug Corp for 60 units of Scemblix 40 mg tablets, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAATHDelivery Order
The Defense Logistics Agency awarded a $13,259.50 delivery order to AmerisourceBergen Drug Corp for Scemblix 40 mg tablets (60-count units) on August 8, 2025, with an ultimate completion date of August 29, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp's extensive federal contract portfolio demonstrates its capability to meet diverse medical supply requirements through open competition, with deliveries spanning specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 8/8/25 |